S1.E10: COVID-19 AND SKIN
The COVID-19 virus is deadly. It is insidious, and it is going to be with us for a very long time. How do we continue to provide a clinical service in the grips of a pandemic? What are the cutaneous manifestations of COVID-19? How common are these cutaneous manifestations? What does it mean when a patient presents with perniosis in this time? What about our patients who are immunosuppressed on biologics, what do we do with them?
These are complex and difficult questions, and to help us answer these, we are very fortunate to have with us two eminent dermatologists from the USA, Professor Kanade Shinkai from UCSF and Dr Esther Freeman at Harvard.
Professor Kanade Shinkai is the Professor of Clinical Dermatology and faculty member of the University of California San Francisco (UCSF) Department of Dermatology. Kanade specializes in medical dermatology. She is passionate about medical education and now serves as the vice-chair for education for that department. She's also the current editor-in-chief of JAMA Dermatology.
Dr Esther Freeman trained as an epidemiologist with a PhD from the London School of Tropical Medicine, as well as being a dermatologist. Currently, Esther is the director of Global Health Dermatology at Massachusetts General Hospital in Boston, the chair of the Clinical Guidelines Committee at the American Academy of Dermatology, and a member of the AAD COVID-19 Task Force. She directs the COVID-19 Dermatology Registry, which is an international effort with over 1,000 cases from 40 countries. She has published seminal papers on the cutaneous manifestations of COVID-19.
- Shinkai K, Bruckner AL. Dermatology and COVID-19. JAMA [Internet]. 2020 Sep 22;324(12):1133. Available from: https://jamanetwork.com/journals/jama/fullarticle/2770862
- Colmenero I, Santonja C, Alonso-Riaño M, Noguera-Morel L, Hernández-Martín A, Andina D, et al. SARS-CoV-2 endothelial infection causes COVID-19 chilblains: histopathological, immunohistochemical and ultrastructural study of seven paediatric cases. Br J Dermatol. 2020;0–1.
- Freeman EE, McMahon DE, Lipoff JB, Rosenbach M, Kovarik C, Takeshita J, et al. Pernio-like skin lesions associated with COVID-19: A case series of 318 patients from 8 countries. J Am Acad Dermatol [Internet]. 2020 Aug;83(2):486–92.
- Freeman EE, McMahon DE, Lipoff JB, Rosenbach M, Kovarik C, Desai SR, et al. The spectrum of COVID-19–associated dermatologic manifestations: An international registry of 716 patients from 31 countries. J Am Acad Dermatol [Internet]. 2020 Oct;83(4):1118–29.
- Wang C, Rademaker M, Baker C, Foley P. COVID-19 and the use of immunomodulatory and biologic agents for severe cutaneous disease: An Australian/New Zealand consensus statement. Australas J Dermatol. 2020;61(3):210–6.
- Hernandez C, Bruckner AL. Focus on “COVID Toes.” JAMA Dermatology [Internet]. 2020 Sep 1;156(9):1003.
- Freeman EE, McMahon DE, Fitzgerald ME, Fox LP, Rosenbach M, Takeshita J, et al. The American Academy of Dermatology COVID-19 registry: Crowdsourcing dermatology in the age of COVID-19. J Am Acad Dermatol [Internet]. 2020 Aug;83(2):509–10.
- JAMA Network COVID-19 hub
- The LANCET COVID-19 Resource Centre
- Journal of the American Academy of Dermatology (JAAD)
- American Academy of Dermatology (AAD) Coronavirus Resources
- DermNet NZ – COVID-19
- Humerus Hacks, an excellent podcast series for medical students
- Learn Derm podcasts for dermatologists and dermatology registrars (US based)
Please rate and review this podcast. We would really appreciate your feedback. This will help us to develop Spot Diagnosis for all our listeners.
If you like it, share it too.
SPOT DIAGNOSIS MAILING LIST
Subscribe to the Spot Diagnosis mailing list to be kept in the loop regarding new episodes, additional resources, and more!